Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial


Category: General

Date: May 2014

Author: Paolo Mannelli

Type: Article

These findings suggest that two thirds or more of opioid addicted individuals who are interested in extended release injectable naltrexone (XR-NTX) treatment may be able to be detoxified and started on XR-NTX in an outpatient setting.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Not Finding What You're Looking For?

Fill out the form below to let us know.